The trial is assessing single and multiple ascending doses of MB‑388 in healthy volunteers.

Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two confirmed responders remains on study ~40 weeks after ...

Genetox, a latecomer in the botulinum toxin market, has completed the administration and follow-up observation of subjects in ...

Gilead Sciences' primary biliary cholangitis (PBC) therapy, Livdelzi (seladelpar), has been shown to diminish a key marker of ...

(9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific ...

Zydus Therapeutics, a subsidiary of Zydus Lifesciences Limited, has announced encouraging results from its Phase 2b clinical ...

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA ...

Rivia Expands Clinical Trial Intelligence Platform with New AI-Powered Data Findings Module New module enables continuous, automated review of clinical trial data, helping drug developers identify ...

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company developing potentially ...

Ractigen Therapeutics, a leading clinical-stage biopharmaceutical company developing innovative small activating RNA (saRNA) ...

Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadin Protocol ...